HemaSphere (Jun 2022)
S117: EVI1 DRIVES LEUKEMOGENESIS THROUGH ABERRANT ERG ACTIVATION
- J. Schmoellerl,
- I. Barbosa,
- M. Minnich,
- F. Andersch,
- L. Smeenk,
- M. Havermans,
- T. Eder,
- T. Neumann,
- J. Jude,
- M. Fellner,
- A. Ebert,
- M. Steininger,
- R. Delwel,
- F. Grebien,
- J. Zuber
Affiliations
- J. Schmoellerl
- 1 Research Institute of Molecular Pathology (IMP), Vienna, Austria
- I. Barbosa
- 1 Research Institute of Molecular Pathology (IMP), Vienna, Austria
- M. Minnich
- 1 Research Institute of Molecular Pathology (IMP), Vienna, Austria
- F. Andersch
- 1 Research Institute of Molecular Pathology (IMP), Vienna, Austria
- L. Smeenk
- 2 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
- M. Havermans
- 2 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
- T. Eder
- 3 Institute for Medical Biochemistry, University of Veterinary Medicine Vienna, Vienna, Austria
- T. Neumann
- 1 Research Institute of Molecular Pathology (IMP), Vienna, Austria
- J. Jude
- 1 Research Institute of Molecular Pathology (IMP), Vienna, Austria
- M. Fellner
- 1 Research Institute of Molecular Pathology (IMP), Vienna, Austria
- A. Ebert
- 1 Research Institute of Molecular Pathology (IMP), Vienna, Austria
- M. Steininger
- 1 Research Institute of Molecular Pathology (IMP), Vienna, Austria
- R. Delwel
- 2 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
- F. Grebien
- 3 Institute for Medical Biochemistry, University of Veterinary Medicine Vienna, Vienna, Austria
- J. Zuber
- 1 Research Institute of Molecular Pathology (IMP), Vienna, Austria
- DOI
- https://doi.org/10.1097/01.HS9.0000843360.50139.04
- Journal volume & issue
-
Vol. 6
pp. 18 – 19
Abstract
No abstracts available.